Foss H D, Araujo I, Demel G, Klotzbach H, Hummel M, Stein H
Institute of Pathology, Klinikum Benjamin Franklin, Free University of Berlin, Germany.
J Pathol. 1997 Sep;183(1):44-50. doi: 10.1002/(SICI)1096-9896(199709)183:1<44::AID-PATH1103>3.0.CO;2-I.
Vascular endothelial growth factor (VEGF) is one of the main angiogenic cytokines in human solid tumours and inhibition of VEGF-induced angiogenesis suppresses tumour growth. Some groups of malignant lymphoma, including peripheral T-cell lymphomas and Hodgkin's disease, are characterized by a conspicuous proliferation of small vessels. To test the hypothesis that VEGF may also be involved in the angiogenesis in lymphomas and other lesions of the lymphoid system, VEGF expression was analysed in tissues, employing in situ hybridization with a 35S-labelled RNA probe specific for this cytokine. Significant expression of VEGF transcripts was observed in Hodgkin's disease and peripheral T-cell lymphomas, particularly of the angioimmunoblastic type. In contrast, expression of this cytokine was minimal or absent in follicle centre lymphoma and chronic lymphocytic leukemia of B-cell type. VEGF was mainly observed in reactive non-lymphoid CD68-negative cells, which probably represent fibroblasts or myofibroblasts. In normal and ulcerated tonsils, VEGF was expressed in the squamous epithelium but only rarely found in the lymphoid tissue. Although infectious mononucleosis tonsils contained high numbers of VEGF-positive cells in the interfollicular zone, expression of this cytokine was not found in Epstein-Barr virus (EBV)-infected cells, as determined by simultaneous in situ hybridization for VEGF and EBV-encoded small nuclear RNAs (EBER). In 5/8 cases of Castleman's disease, germinal centres containing small vessels also showed expression of VEGF, in contrast to normal tonsillar germinal centres which are devoid of both vessels and VEGF transcripts. It is concluded that VEGF may be involved in the induction of the angiogenesis of both peripheral T-cell lymphomas and Hodgkin's disease, but not in low-grade B-cell lymphomas. In contradistinction to solid tumours, in which this cytokine is commonly secreted by the tumour cells themselves, in malignant lymphoma VEGF is not a product of neoplastic cells. Vascularization of germinal centres in Castleman's disease may also be a consequence of abnormal local expression of VEGF.
血管内皮生长因子(VEGF)是人类实体瘤中主要的血管生成细胞因子之一,抑制VEGF诱导的血管生成可抑制肿瘤生长。包括外周T细胞淋巴瘤和霍奇金病在内的一些恶性淋巴瘤组,其特征是小血管明显增殖。为了验证VEGF也可能参与淋巴瘤和淋巴系统其他病变血管生成的假说,采用针对该细胞因子的35S标记RNA探针进行原位杂交,分析组织中的VEGF表达。在霍奇金病和外周T细胞淋巴瘤,特别是血管免疫母细胞型中,观察到VEGF转录本的显著表达。相比之下,在滤泡中心淋巴瘤和B细胞型慢性淋巴细胞白血病中,这种细胞因子的表达极少或不存在。VEGF主要在反应性非淋巴细胞CD68阴性细胞中观察到,这些细胞可能代表成纤维细胞或肌成纤维细胞。在正常和溃疡的扁桃体中,VEGF在鳞状上皮中表达,但在淋巴组织中很少发现。尽管传染性单核细胞增多症扁桃体在滤泡间区含有大量VEGF阳性细胞,但通过同时对VEGF和EB病毒编码的小核RNA(EBER)进行原位杂交测定,在EB病毒感染的细胞中未发现这种细胞因子的表达。在8例Castleman病中的5例中,含有小血管的生发中心也显示出VEGF的表达,这与正常扁桃体生发中心缺乏血管和VEGF转录本形成对比。结论是,VEGF可能参与外周T细胞淋巴瘤和霍奇金病的血管生成诱导,但不参与低级别B细胞淋巴瘤。与实体瘤不同,在实体瘤中这种细胞因子通常由肿瘤细胞自身分泌,在恶性淋巴瘤中VEGF不是肿瘤细胞的产物。Castleman病中生发中心的血管化也可能是VEGF异常局部表达的结果。